Hainan Haiyao (000566.SZ): The innovative drug Fluconidine Capsules for the treatment of liver fibrosis has completed Phase II clinical trials.

Chi-Tong Finance APP News, Hainan Haiyao (000566.SZ) has issued a public announcement regarding abnormal fluctuations in stock trading, stating that the company's innovative anti-liver fibrosis drug Fufinikone capsules have completed Phase II clinical trials, and the Phase III clinical research is currently progressing as planned; the company's innovative anti-epilepsy drug Pencobam tablets have completed Phase IIa clinical trials, and Phase IIb clinical trials are currently progressing as planned. New drug research and development is characterized by long cycles, high investment, and high risks. There are many uncertainties in the clinical trial process and results, and uncertainties exist in whether approval for market listing can be obtained. In the short term, it will not have a significant impact on the company's performance.